{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:55:50Z","timestamp":1790708150673,"version":"4.1.0"},"reference-count":34,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Hyperkalaemia is common in patients with heart failure. It limits the initiation, optimisation and continuation of guideline-directed medical therapy, particularly mineralocorticoid receptor antagonists. Two potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), have emerged as strategies to address this barrier. SZC is an inorganic crystalline compound that binds potassium in exchange for sodium and hydrogen throughout the gastrointestinal tract, resulting in rapid potassium lowering, whereas patiromer is a non-absorbed organic polymer that exchanges potassium for calcium in the colon and has a slower onset of action. Both agents have demonstrated efficacy in maintaining normokalaemia and enabling the continuation of renin\u2013angiotensin\u2013aldosterone system inhibitor therapy in heart failure. Differences in electrolyte effects and tolerability have clinical implications: patiromer is associated with hypomagnesaemia, while SZC delivers a sodium load that may predispose patients to fluid retention. However, no head-to-head randomised trials are available and evidence for improvement in heart failure morbidity or mortality remains limited, underscoring the need for adequately powered outcome studies.<\/jats:p>","DOI":"10.15420\/cfr.2026.10","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:56:02Z","timestamp":1790704562000},"source":"Crossref","is-referenced-by-count":0,"title":["Overcoming Hyperkalaemia to Optimise Heart Failure Therapy: The Emerging Role of Novel Potassium Binders"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8447-6118","authenticated-orcid":false,"given":"Sudesh","family":"Prajapathi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01rs0zz87","id-type":"ROR","asserted-by":"publisher"}],"name":"All India Institute of Medical Sciences Bhopal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-7580","authenticated-orcid":false,"given":"Akshyaya","family":"Pradhan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00gvw6327","id-type":"ROR","asserted-by":"publisher"}],"name":"King George's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-6505","authenticated-orcid":false,"given":"Kunal","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Agarwala","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ec7xj20","id-type":"ROR","asserted-by":"publisher"}],"name":"Jaswant Rai Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2621","authenticated-orcid":false,"given":"Marco Alfonso","family":"Perrone","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02p77k626","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Rome Tor Vergata"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Khan SS, Campia U, Chioncel O, et al. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). Am J Cardiol 2015;115:790\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2014.12.045; PMID:\u00a025728846.","DOI":"10.1016\/j.amjcard.2014.12.045"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001; PMID:\u00a010471456.","DOI":"10.1056\/NEJM199909023411001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492; PMID:\u00a021073363.","DOI":"10.1056\/NEJMoa1009492"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107; PMID:\u00a039225278.","DOI":"10.1056\/NEJMe2410904"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Chopra V. The aldosterone story: new chapters. Card Fail Rev 2025;11:e17. https:\/\/doi.org\/10.15420\/cfr.2025.16; PMID:\u00a040771309.","DOI":"10.15420\/cfr.2025.16"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wong SWS, Zhang G, Norman P, et al. Polysulfonate resins in hyperkalemia: a systematic review. Can J Kidney Health Dis 2020;7. https:\/\/doi.org\/10.1177\/2054358120965838; PMID:\u00a033240515.","DOI":"10.1177\/2054358120965838"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2836\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.021; PMID:\u00a032498812.","DOI":"10.1016\/j.jacc.2020.04.021"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF trial). Eur Heart J 2011;32:820\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehq502; PMID:\u00a021208974.","DOI":"10.1093\/eurheartj\/ehq502"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Hougen I, Leon SJ, Whitlock R, et al. Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort. Kidney Int Rep 2021;6:1309\u201316. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.038; PMID:\u00a034013109.","DOI":"10.1016\/j.ekir.2021.02.038"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalemia. Pharmacotherapy 2017;37:401\u201311. https:\/\/doi.org\/10.1002\/phar.1906; PMID:\u00a028122118.","DOI":"10.1002\/phar.1906"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015;88:1427\u201333. https:\/\/doi.org\/10.1038\/ki.2015.270; PMID:\u00a026376130.","DOI":"10.1038\/ki.2015.270"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1410853; PMID:\u00a025415805.","DOI":"10.1056\/NEJMoa1410853"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)32135-X; PMID:\u00a031533906.","DOI":"10.1016\/S0140-6736(19)32135-X"},{"key":"ref13","unstructured":"Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 2022;43:4362\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401; PMID:\u00a035900838."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. N Engl J Med 2015;372:1577\u20138. https:\/\/doi.org\/10.1056\/NEJMc1500353; PMID:\u00a025875277.","DOI":"10.1056\/NEJMc1500353"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One 2014;9:e114686. https:\/\/doi.org\/10.1371\/journal.pone.0114686; PMID:\u00a025531770.","DOI":"10.1371\/journal.pone.0114686"},{"key":"ref16","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic review report: sodium zirconium cyclosilicate (Lokelma). May 2020. Ottawa: Canadian Agency for Drugs and Technologies in Health. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563723 (accessed 16\u00a0January 2026)."},{"key":"ref17","unstructured":"Sodium zirconium cyclosilicate. DrugBank. https:\/\/go.drugbank.com\/drugs\/DB14048 (accessed 16\u00a0January 2026)."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Levien TL, Baker DE. Sodium zirconium cyclosilicate. Hosp Pharm 2019;54:12\u20139. https:\/\/doi.org\/10.1177\/0018578718817470; PMID:\u00a030718929.","DOI":"10.1177\/0018578718817470"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int 2015;88:404\u201311. https:\/\/doi.org\/10.1038\/ki.2014.382; PMID:\u00a025651363","DOI":"10.1038\/ki.2014.382"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372:222\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1411487; PMID:\u00a025415807.","DOI":"10.1056\/NEJMoa1411487"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014;312:2223\u201333. https:\/\/doi.org\/10.1001\/jama.2014.15688; PMID:\u00a025402495.","DOI":"10.1001\/jama.2014.15688"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol 2019;50:473\u201380. https:\/\/doi.org\/10.1159\/000504078; PMID:\u00a031658466.","DOI":"10.1159\/000504078"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Zannad F, Hsu BG, Maeda Y, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized placebo-controlled HARMONIZE-Global study. ESC Heart Fail 2020;7:55\u201365. https:\/\/doi.org\/10.1002\/ehf2.12561; PMID:\u00a031944628.","DOI":"10.1002\/ehf2.12561"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant 2021;36:137\u201350. https:\/\/doi.org\/10.1093\/ndt\/gfz285; PMID:\u00a032030422.","DOI":"10.1093\/ndt\/gfz285"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Tardif JC, Rouleau J, Chertow GM, et al. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail 2023;10:1066\u201376. https:\/\/doi.org\/10.1002\/ehf2.14268; PMID:\u00a036564955.","DOI":"10.1002\/ehf2.14268"},{"key":"ref26","unstructured":"Kosiborod MN, Cherney DZI, Desai AS, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol 2025;85:971\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.014; PMID:\u00a039566872."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Hida Y, Imamura T, Kinugawa K. Prognostic impact of long-term sodium zirconium cyclosilicate-integrated medical therapy in patients with systolic heart failure. J Clin Med 2025;14:2836. https:\/\/doi.org\/10.3390\/jcm14082836; PMID:\u00a040283666.","DOI":"10.3390\/jcm14082836"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shimada H, Mizuno K, Kawakami K. Comparative effectiveness of sodium zirconium cyclosilicate versus calcium polystyrene sulfonate for patients with heart failure. Heart Vessels 2025;41:246\u201357. https:\/\/doi.org\/10.1007\/s00380-025-02609-4; PMID:\u00a041055706.","DOI":"10.1007\/s00380-025-02609-4"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Desai NR, Kammerer J, Budden J, et al. The Association of heart failure and edema events between patients initiating sodium zirconium cyclosilicate or patiromer. Kidney360 2024;5:1835\u201343. https:\/\/doi.org\/10.34067\/KID.0000000586; PMID:\u00a039303023.","DOI":"10.34067\/KID.0000000586"},{"key":"ref30","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref31","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure. Circulation 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID:\u00a035363499."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol 2021;77:1397\u2013407. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.044; PMID:\u00a033736821.","DOI":"10.1016\/j.jacc.2021.01.044"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156\u201362. https:\/\/doi.org\/10.1001\/archinternmed.2009.132; PMID:\u00a019546417.","DOI":"10.1001\/archinternmed.2009.132"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2026.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:56:12Z","timestamp":1790704572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2026.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.15420\/cfr.2026.10","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"e32"}}